Table 2.
Publications of Adult DM That Report Efficacy of JAK Inhibitors in Muscle Disease Activity
| Publication | N* | Time to Outcome |
Baseline Muscle Strength Assessment |
Posttreatment Muscle Strength Assessment |
Other Clinical Improvements |
|---|---|---|---|---|---|
| Hornung et al (2014) (8) | 1 | 2 months | NR | NR | Patient regained muscle strength |
| Paik and Christopher-Stine (2017) (12) | 1 | 2–6 months | Handheld dynamometry, 4/5 | Handheld dynamometry, 5/5 | Muscle strength improved within 2 months; prednisone tapered at 2 months without worsening of muscle weakness |
| Allenbach et al (2018) (63)† | 1 | 3 months | Muscle strength improved | ||
| Ladislau et al (2018) (20)† | 2 | 3 months | Mean MRC, 3 | Mean MRC, 5 | Muscle strength improved |
| Moghadam-Kia et al (2019) (37) | 1 | 6 months | NR | NR | Improved MMT at 6 months in patient with active muscle disease |
| Wendel et al (2019) (23) | 1 | 12, 28 weeks | NR | NR | Muscle strength improved after 12 weeks |
| Delvino et al (2020) (30) | 1 | 3–12 months | NR | NR | Subjective improvement in strength within 3 months, which was sustained at 12 months |
| Fetter et al (2020) (31) | 1 | 4 months | NR | NR | Noticeable improvement in muscle strength |
| Jalles et al (2020) (35) | 1 | 4 months | NR | NR | Patient regained muscle strength; clinical remission |
| Navarro-Navarro et al (2020) (21) | 1 | 20 weeks | NR | NR | Subjective improvement in strength and fatigue; muscle enzymes returned to normal range |
| Williams and McKinney (2020) (40) | 1 | 6 months | NR | NR | Patient experienced regained muscle strength |
| Min et al (2021) (19) | 2 active, 2 mild | 1–2 months | NR | NR | Resolution of muscle disease activity in patients with refractory muscle weakness; subjective improvement in strength and fatigue in patients with mild muscle weakness |
| Kurtzman et al (2016) (11)‡ | 2 mild | 4 weeks | NR | NR | Subjective improvement in strength and fatigue |
| Paik et al (2021a) (13) | 1 | 12 weeks | MMT-8, 127 | MMT-8, 136 | Evidence of edema on baseline muscle MRI, which improved by week 12 |
DM, dermatomyositis; MMT, manual muscle testing; MRC, Medical Research Council MMT Scale; MRI, magnetic resonance imaging; NR, not reported.
*
Number of patients with active muscle disease; publication may have included additional patients without active muscle disease.
†
Some or all patients likely to have been reported in another publication.
‡
Some or all patients likely to have been reported in Min et al (2021) (19).